RXRX – Recursion Pharmaceuticals, Inc.
Float Short %
37.91
Margin Of Safety %
Put/Call OI Ratio
0.23
EPS Next Q Diff
0.04
EPS Last/This Y
0.08
EPS This/Next Y
0.44
Price
4.97
Target Price
7
Analyst Recom
2.25
Performance Q
-18.82
Relative Volume
1.32
Beta
0.94
Ticker: RXRX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | RXRX | 4.24 | 0.24 | 0.30 | 416497 |
| 2025-12-29 | RXRX | 4.13 | 0.25 | 0.32 | 407288 |
| 2025-12-30 | RXRX | 4.11 | 0.25 | 0.25 | 415344 |
| 2025-12-31 | RXRX | 4.08 | 0.26 | 0.23 | 420050 |
| 2026-01-02 | RXRX | 4.2 | 0.26 | 0.22 | 422482 |
| 2026-01-05 | RXRX | 4.36 | 0.26 | 0.16 | 415527 |
| 2026-01-06 | RXRX | 4.56 | 0.25 | 0.11 | 428173 |
| 2026-01-07 | RXRX | 4.84 | 0.25 | 0.13 | 438226 |
| 2026-01-08 | RXRX | 4.7 | 0.24 | 0.14 | 445316 |
| 2026-01-09 | RXRX | 4.66 | 0.23 | 0.19 | 447194 |
| 2026-01-12 | RXRX | 4.82 | 0.23 | 0.30 | 438531 |
| 2026-01-13 | RXRX | 4.7 | 0.23 | 0.22 | 448727 |
| 2026-01-14 | RXRX | 4.85 | 0.23 | 0.20 | 451642 |
| 2026-01-15 | RXRX | 4.64 | 0.22 | 0.18 | 453318 |
| 2026-01-16 | RXRX | 4.66 | 0.23 | 0.20 | 455505 |
| 2026-01-20 | RXRX | 4.41 | 0.24 | 0.36 | 270634 |
| 2026-01-21 | RXRX | 4.61 | 0.24 | 0.13 | 282235 |
| 2026-01-22 | RXRX | 4.96 | 0.23 | 0.07 | 300042 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | RXRX | 4.25 | 39.0 | - | -1.61 |
| 2025-12-29 | RXRX | 4.12 | 39.0 | - | -1.61 |
| 2025-12-30 | RXRX | 4.11 | 39.0 | - | -1.61 |
| 2025-12-31 | RXRX | 4.09 | 39.0 | - | -1.61 |
| 2026-01-02 | RXRX | 4.21 | 39.0 | - | -1.61 |
| 2026-01-05 | RXRX | 4.36 | 39.0 | - | -1.61 |
| 2026-01-06 | RXRX | 4.55 | 39.0 | - | -1.61 |
| 2026-01-07 | RXRX | 4.86 | 39.0 | - | -1.61 |
| 2026-01-08 | RXRX | 4.70 | 39.0 | - | -1.61 |
| 2026-01-09 | RXRX | 4.66 | 40.6 | - | -1.61 |
| 2026-01-12 | RXRX | 4.83 | 40.6 | - | -1.61 |
| 2026-01-13 | RXRX | 4.70 | 40.6 | - | -1.61 |
| 2026-01-14 | RXRX | 4.86 | 40.6 | - | -1.61 |
| 2026-01-15 | RXRX | 4.64 | 40.6 | - | -1.61 |
| 2026-01-16 | RXRX | 4.66 | 40.6 | - | -1.61 |
| 2026-01-20 | RXRX | 4.39 | 40.6 | - | -1.61 |
| 2026-01-21 | RXRX | 4.62 | 40.6 | - | -1.61 |
| 2026-01-22 | RXRX | 4.97 | 40.6 | - | -1.61 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | RXRX | -1.70 | 3.91 | 35.62 |
| 2025-12-29 | RXRX | -1.70 | 1.15 | 35.14 |
| 2025-12-30 | RXRX | -1.96 | 1.15 | 35.14 |
| 2025-12-31 | RXRX | -1.99 | 1.15 | 35.14 |
| 2026-01-02 | RXRX | -1.99 | 1.15 | 35.14 |
| 2026-01-05 | RXRX | -1.99 | 1.15 | 35.13 |
| 2026-01-06 | RXRX | -1.99 | 1.15 | 35.13 |
| 2026-01-07 | RXRX | -2.04 | 1.15 | 35.13 |
| 2026-01-08 | RXRX | -2.29 | 1.15 | 35.13 |
| 2026-01-09 | RXRX | -2.29 | 1.15 | 35.13 |
| 2026-01-12 | RXRX | -2.27 | 1.08 | 35.13 |
| 2026-01-13 | RXRX | -2.29 | 1.08 | 37.85 |
| 2026-01-14 | RXRX | -2.30 | 1.08 | 37.85 |
| 2026-01-15 | RXRX | -2.30 | 1.08 | 37.91 |
| 2026-01-16 | RXRX | -2.28 | 1.08 | 37.91 |
| 2026-01-20 | RXRX | -2.28 | 0.80 | 37.91 |
| 2026-01-21 | RXRX | -2.28 | 0.80 | 37.91 |
| 2026-01-22 | RXRX | -2.28 | 0.80 | 37.91 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.36
Avg. EPS Est. Current Quarter
-0.32
Avg. EPS Est. Next Quarter
-0.32
Insider Transactions
-2.28
Institutional Transactions
0.8
Beta
0.94
Average Sales Estimate Current Quarter
24
Average Sales Estimate Next Quarter
16
Fair Value
Quality Score
22
Growth Score
36
Sentiment Score
27
Actual DrawDown %
88.4
Max Drawdown 5-Year %
Target Price
7
P/E
Forward P/E
PEG
P/S
59.09
P/B
2.33
P/Free Cash Flow
EPS
-1.81
Average EPS Est. Cur. Y
-1.61
EPS Next Y. (Est.)
-1.17
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1637.81
Relative Volume
1.32
Return on Equity vs Sector %
-95.6
Return on Equity vs Industry %
-79.7
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Recursion Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 800
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
stock quote shares RXRX – Recursion Pharmaceuticals, Inc. Stock Price stock today
news today RXRX – Recursion Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RXRX – Recursion Pharmaceuticals, Inc. yahoo finance google finance
stock history RXRX – Recursion Pharmaceuticals, Inc. invest stock market
stock prices RXRX premarket after hours
ticker RXRX fair value insiders trading